Book Value per Share: Xenon Pharmaceuticals Inc (XENE)

Xenon Pharmaceuticals (XENE) - corporate logo

The price visualization on GURU.Markets for Xenon Pharmaceuticals (XENE) demonstrates the dynamics of a biopharmaceutical business focused on treating pain syndromes and epilepsy, working with medical centers and private individuals. The current indicator is 12.88. The stability of the scientific core and targeted hiring of top management support R&D momentum. Meanwhile, the company's success depends on test outcomes rather than market cycles.

Xenon Pharmaceuticals Inc. (XENE) Equity per Share: for the period 07/04/2022 - 10/28/2026

xenon-pharma.com - analytical breakdowns and key metrics (XENE)

- price and consensus price forecast:
Price Chart Xenon Pharmaceuticals Inc|XENE - Broker Consensus Forecast
- market capitalization data:
Market Capitalization Xenon|XENE - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Xenon Pharmaceuticals|XENE - Accounting Capitalization|Market Capitalization to Book Value Ratio xenon-pharma.com|XENE - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Xenon Pharmaceuticals|XENE - Long-Term Debt to Capital|Short-Term Debt to Equity Xenon|XENE - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Xenon|XENE - Long-Term Debt|Company Current Liabilities Xenon Pharmaceuticals
Fundamental company valuation:Xenon Pharmaceuticals Inc, XENE
Manufactured products of Xenon

Fundamental risks are determined by comparing the market price with the real cost of capital. For Xenon Pharmaceuticals (XENE), the stability of this valuation depends on the logistics efficiency of innovative molecules and the diversification of raw material supplies. The dynamics of the net asset value per share reflect the liquidation value of the shareholder's stake minus liabilities. When quotes exceed this metric, it signals overvaluation; conversely, a deep discount may indicate hidden liquidity issues.

Competitor analysis

Biogen Corp (BIIB) - Net Assets per Single Share|NBIX - Equity per Share|Book Value per Share RGC|AXSM (axsome.com) - Net Asset Value per Share|Net Assets per Single Share ACADIA Pharmaceuticals Inc. (ACAD)|Equity per Share Viking Therapeutics Inc|Supernus Pharma - Book Value per Share|Net Asset Value per Share Catalyst Corp CPRX|Accounting Value per Share DNLI (Denali Therapeutics)|harmonybiosciences.com - Book Value per Share|Net Assets per Single Share Biohaven (BHVN)|AMLX: Accounting Value of a Share|Net Assets per Single Share TRVI|Net Asset Value per Share Praxis Corp|Accounting Value per Share Anavex Life Sciences (AVXL)|Equity per Share ceribell.com|Prothena Biosciences - Book Value per Share|Net Asset Value per Share ALEC (alector.com)|ANNX - Net Assets per Single Share|Omeros Corp - Equity per Share|NGNE (Neurogene Inc.) - Net Assets per Single Share|ACIU: Net Asset Value per Share|Net Assets per Single Share Voyager Therapeutics, Inc.|Equity per Share Neumora|SCLX - Accounting Value per Share|Accounting Value of a Share TVGN|ACOG - Net Assets per Single Share|Share Book Value Cognition Therapeutics Inc. (CGTX)|Book Value per Share Inhibikase Therapeutics, Inc.|Accounting Value of a Share Cassava Sciences Inc SAVA|Assertio Therapeutics - Book Value per Share|COYA: Book Value per Share|Net Assets per Single Share vistagen.com VTGN|OVID (Ovid Therapeutics) - Accounting Value of a Share|Net Assets per Single Share ABOS|Accounting Value per Share CervoMed, Inc.|Book Value per Share ATHE|Book Value per Share clene.com (CLNN)|PepGen - Book Value per Share|Accounting Value per Share Jupiter Neurosciences, Inc. JUNS|RLMD (Relmada Therapeutics, Inc.) - Book Value per Share|Annovis Bio Inc (ANVS) - Net Asset Value per Share|GRCE: Accounting Value per Share|Book Value per Share Firefly Neuro|ANEW Medical (KLTO) - Accounting Value per Share|Book Price of a Share NeuroSense Therapeutics, Ltd.|RVPH (Reviva Pharmaceuticals Holdings, Inc.) - Book Value per Share|Net Assets per Share metaviatx.com (MTVA)|NeurAxis, Inc - Book Value per Share|Accounting Value per Share Helius Medical Technologies, Inc. HSDT|Passage Bio Corp - Book Value per Share|NEUP: Book Value per Share|Minerva Neurosciences, Inc. (NERV) - Net Assets per Single Share|ATHA (Athira Pharma Inc) - Net Assets per Single Share|ADXN: Net Assets per Single Share|Net Assets per Share Alzamend (ALZN)|Accounting Value per Share Cyclerion Therapeutics CYCN|Equity per Share protagenic.com (PTIX)|KTTA: Book Value per Share|Cortigent Inc - Net Asset Value per Share|Avenue Therapeutics, Inc (ATXI) - Net Assets per Single Share|BCLI - Equity per Share|Book Value per Share CARA|CHRO (chromocell.com) - Net Asset Value per Share|Net Assets per Single Share Eliem Therapeutics, Inc. (ELYM)|Equity per Share Intra-Cellular|Longboard Pharma - Book Value per Share|Net Asset Value per Share Marinus Pharma MRNS|Accounting Value per Share NKGN (NKGen Biotech, Inc.)|neurobopharma.com - Book Value per Share|Net Assets per Single Share Sage Therapeutics (SAGE)|SNPX: Accounting Value of a Share|Net Assets per Single Share TRVN|Net Asset Value per Share Vigil Neuroscience, Inc.|Accounting Value per Share Anew Medical (WENA)|Equity per Share cerevel.com